PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
GSK vs. SHEL
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Key characteristics


GSKSHEL
YTD Return18.11%10.79%
1Y Return22.43%28.40%
3Y Return (Ann)8.78%27.77%
5Y Return (Ann)5.67%6.96%
10Y Return (Ann)2.50%4.00%
Sharpe Ratio1.331.47
Daily Std Dev18.07%18.23%
Max Drawdown-55.72%-67.46%
Current Drawdown-1.78%-1.58%

Fundamentals


GSKSHEL
Market Cap$83.99B$234.25B
EPS$2.99$5.70
PE Ratio13.7512.85
PEG Ratio1.093.19
Revenue (TTM)$30.33B$316.62B
Gross Profit (TTM)$19.92B$97.31B
EBITDA (TTM)$10.30B$46.22B

Correlation

-0.50.00.51.00.3

The correlation between GSK and SHEL is 0.34, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Performance

GSK vs. SHEL - Performance Comparison

In the year-to-date period, GSK achieves a 18.11% return, which is significantly higher than SHEL's 10.79% return. Over the past 10 years, GSK has underperformed SHEL with an annualized return of 2.50%, while SHEL has yielded a comparatively higher 4.00% annualized return. The chart below displays the growth of a $10,000 investment in both assets, with all prices adjusted for splits and dividends.


3,600.00%3,800.00%4,000.00%4,200.00%4,400.00%4,600.00%4,800.00%December2024FebruaryMarchAprilMay
4,860.52%
4,369.44%
GSK
SHEL

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


GlaxoSmithKline plc

Shell plc

Risk-Adjusted Performance

GSK vs. SHEL - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for GlaxoSmithKline plc (GSK) and Shell plc (SHEL). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


GSK
Sharpe ratio
The chart of Sharpe ratio for GSK, currently valued at 1.33, compared to the broader market-2.00-1.000.001.002.003.004.001.33
Sortino ratio
The chart of Sortino ratio for GSK, currently valued at 2.05, compared to the broader market-4.00-2.000.002.004.006.002.05
Omega ratio
The chart of Omega ratio for GSK, currently valued at 1.24, compared to the broader market0.501.001.501.24
Calmar ratio
The chart of Calmar ratio for GSK, currently valued at 0.92, compared to the broader market0.002.004.006.000.92
Martin ratio
The chart of Martin ratio for GSK, currently valued at 5.38, compared to the broader market-10.000.0010.0020.0030.005.38
SHEL
Sharpe ratio
The chart of Sharpe ratio for SHEL, currently valued at 1.47, compared to the broader market-2.00-1.000.001.002.003.004.001.47
Sortino ratio
The chart of Sortino ratio for SHEL, currently valued at 2.06, compared to the broader market-4.00-2.000.002.004.006.002.06
Omega ratio
The chart of Omega ratio for SHEL, currently valued at 1.26, compared to the broader market0.501.001.501.26
Calmar ratio
The chart of Calmar ratio for SHEL, currently valued at 2.67, compared to the broader market0.002.004.006.002.67
Martin ratio
The chart of Martin ratio for SHEL, currently valued at 7.19, compared to the broader market-10.000.0010.0020.0030.007.19

GSK vs. SHEL - Sharpe Ratio Comparison

The current GSK Sharpe Ratio is 1.33, which roughly equals the SHEL Sharpe Ratio of 1.47. The chart below compares the 12-month rolling Sharpe Ratio of GSK and SHEL.


Rolling 12-month Sharpe Ratio0.000.501.001.502.00December2024FebruaryMarchAprilMay
1.33
1.47
GSK
SHEL

Dividends

GSK vs. SHEL - Dividend Comparison

GSK's dividend yield for the trailing twelve months is around 3.35%, less than SHEL's 3.59% yield.


TTM20232022202120202019201820172016201520142013
GSK
GlaxoSmithKline plc
3.35%3.75%4.72%4.93%5.53%4.35%5.53%5.80%6.89%5.94%6.18%4.49%
SHEL
Shell plc
3.59%3.76%3.48%3.78%5.44%6.14%5.48%4.79%5.88%6.98%4.72%4.25%

Drawdowns

GSK vs. SHEL - Drawdown Comparison

The maximum GSK drawdown since its inception was -55.72%, smaller than the maximum SHEL drawdown of -67.46%. Use the drawdown chart below to compare losses from any high point for GSK and SHEL. For additional features, visit the drawdowns tool.


-25.00%-20.00%-15.00%-10.00%-5.00%0.00%December2024FebruaryMarchAprilMay
-1.78%
-1.58%
GSK
SHEL

Volatility

GSK vs. SHEL - Volatility Comparison

GlaxoSmithKline plc (GSK) has a higher volatility of 5.49% compared to Shell plc (SHEL) at 4.14%. This indicates that GSK's price experiences larger fluctuations and is considered to be riskier than SHEL based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


3.00%4.00%5.00%6.00%7.00%8.00%December2024FebruaryMarchAprilMay
5.49%
4.14%
GSK
SHEL

Financials

GSK vs. SHEL - Financials Comparison

This section allows you to compare key financial metrics between GlaxoSmithKline plc and Shell plc. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities



Values in USD except per share items